For citations:
Mikhaylova I.N., Treshalina N.M., Shubina I.Zh., Manina I.V., Kiselevsky M.V., Lukashev A.N. Antitumor proteinkinase inhibitor imatinib may be regarded as a potential correcting agent for COVID-19 associated pulmonary fibrosis. Advances in Molecular Oncology. 2020;7(4):20-28. (In Russ.) https://doi.org/10.17650/2313-805X-2020-7-4-20-28
Email this article 